Literature DB >> 22205501

Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension.

Yazhini Ravi1, Karuppaiyah Selvendiran, Sarath Meduru, Lucas Citro, Shan Naidu, Mahmood Khan, Brian K Rivera, Chittoor B Sai-Sudhakar, Periannan Kuppusamy.   

Abstract

Pulmonary hypertension (PH) is a disorder of lung vasculature characterized by arterial narrowing. Phosphatase-and-tensin homolog on chromosome 10 (PTEN), associated in the progression of multiple cancers, is implicated in arterial remodeling. However, the involvement of PTEN in PH remains unclear. The objective of the present study was to determine the role of PTEN in pulmonary vascular remodeling using established models of PH. The study used rat models of PH, induced by monocrotaline (MCT) administration (60 mg/kg) or continuous hypoxic exposure (10% oxygen) for 3 weeks. Pulmonary artery smooth muscle cells (SMCs) were used for in vitro confirmation. Development of PH was verified by hemodynamic, morphological and histopathology analyses. PTEN and key downstream proteins in pulmonary and cardiac tissues were analyzed by western blotting and RT-PCR. PTEN was significantly decreased (MCT, 53%; Hypoxia, 40%), pAkt was significantly increased (MCT, 42%; Hypoxia, 55%) in tissues of rats with PH. Similar results were observed in SMCs exposed to hypoxia (1% oxygen) for 48 h. Ubiquitination assay showed that PTEN degradation occurs via proteasomal degradation pathway. Western blotting demonstrated a significant downregulation of cell-cycle regulatory proteins p53 and p27, and upregulation of cyclin-D1 in the lungs of both models. The results showed that PTEN-mediated modulation of PI3K pathway was independent of the focal adhesion kinase and fatty acid synthase. The study, for the first time, established that PTEN plays a key role in the progression of pulmonary hypertension. The findings may have potential for the treatment of pulmonary hypertension using PTEN as a target.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22205501      PMCID: PMC4596526          DOI: 10.1007/s12013-011-9332-z

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  45 in total

1.  Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?

Authors:  N F Voelkel; R M Tuder
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

2.  Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1.

Authors:  H Kimura; Y Kasahara; K Kurosu; K Sugito; Y Takiguchi; M Terai; A Mikata; M Natsume; N Mukaida; K Matsushima; T Kuriyama
Journal:  Lab Invest       Date:  1998-05       Impact factor: 5.662

3.  The rat is a poor animal model for the study of human pulmonary hypertension.

Authors:  D Heath
Journal:  Cardioscience       Date:  1992-03

4.  PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects.

Authors:  Jianhua Huang; Christopher D Kontos
Journal:  J Biol Chem       Date:  2002-01-09       Impact factor: 5.157

5.  PYK2 signaling is required for PDGF-dependent vascular smooth muscle cell proliferation.

Authors:  Jessica Perez; Rebecca A Torres; Petra Rocic; Mary J Cismowski; David S Weber; Victor M Darley-Usmar; Pamela A Lucchesi
Journal:  Am J Physiol Cell Physiol       Date:  2011-03-30       Impact factor: 4.249

6.  Phosphorylation of HDM2 by Akt.

Authors:  Margaret Ashcroft; Robert L Ludwig; Douglas B Woods; Terry D Copeland; H Oliver Weber; Elizabeth J MacRae; Karen H Vousden
Journal:  Oncogene       Date:  2002-03-27       Impact factor: 9.867

7.  Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha.

Authors:  Raphael A Nemenoff; Peter A Simpson; Seth B Furgeson; Nihal Kaplan-Albuquerque; Joseph Crossno; Pamela J Garl; James Cooper; Mary C M Weiser-Evans
Journal:  Circ Res       Date:  2008-03-13       Impact factor: 17.367

8.  Hypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways.

Authors:  Shiro Mizuno; Herman J Bogaard; Norbert F Voelkel; Yukihiro Umeda; Maiko Kadowaki; Shingo Ameshima; Isamu Miyamori; Takeshi Ishizaki
Journal:  Respir Res       Date:  2009-03-06

9.  Left ventricular dysfunction and associated cellular injury in rats exposed to chronic intermittent hypoxia.

Authors:  Ling Chen; Jin Zhang; Tracey X Gan; Ye Chen-Izu; Jeffrey D Hasday; Morris Karmazyn; C William Balke; Steven M Scharf
Journal:  J Appl Physiol (1985)       Date:  2007-11-15

10.  PTEN induces G1 cell cycle arrest and inhibits MMP-9 expression via the regulation of NF-kappaB and AP-1 in vascular smooth muscle cells.

Authors:  Sung-Kwon Moon; Hong-Man Kim; Cheorl-Ho Kim
Journal:  Arch Biochem Biophys       Date:  2004-01-15       Impact factor: 4.013

View more
  18 in total

1.  HOTAIR functions as a competing endogenous RNA to regulate PTEN expression by inhibiting miR-19 in cardiac hypertrophy.

Authors:  Yanjun Lai; Shuai He; Liming Ma; Hong Lin; Biyun Ren; Jing Ma; Xinyu Zhu; Shifang Zhuang
Journal:  Mol Cell Biochem       Date:  2017-03-18       Impact factor: 3.396

Review 2.  Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.

Authors:  Soni Savai Pullamsetti; Rajkumar Savai; Werner Seeger; Elena A Goncharova
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

3.  Protective Effects of Curcumin on Pulmonary Arterial Hypertension.

Authors:  Fatmeh Amin; Shiba Yousefvand; Tannaz Jamialahmadi; Thomas P Johnston; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  PTEN: An Emerging Potential Target for Therapeutic Intervention in Respiratory Diseases.

Authors:  Bangrong Cai; Liu Yang; Young Do Jung; Ying Zhang; Xinguang Liu; Peng Zhao; Jiansheng Li
Journal:  Oxid Med Cell Longev       Date:  2022-06-30       Impact factor: 7.310

5.  Divergent changes of p53 in pulmonary arterial endothelial and smooth muscle cells involved in the development of pulmonary hypertension.

Authors:  Ziyi Wang; Kai Yang; Qiuyu Zheng; Chenting Zhang; Haiyang Tang; Aleksandra Babicheva; Qian Jiang; Meichan Li; Yuqin Chen; Shane G Carr; Kang Wu; Qian Zhang; Angela Balistrieri; Christina Wang; Shanshan Song; Ramon J Ayon; Ankit A Desai; Stephen M Black; Joe G N Garcia; Ayako Makino; Jason X-J Yuan; Wenju Lu; Jian Wang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-25       Impact factor: 5.464

6.  Pulmonary hypertension secondary to left-heart failure involves peroxynitrite-induced downregulation of PTEN in the lung.

Authors:  Yazhini Ravi; Karuppaiyah Selvendiran; Shan K Naidu; Sarath Meduru; Lucas A Citro; Balázs Bognár; Mahmood Khan; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy; Chittoor B Sai-Sudhakar
Journal:  Hypertension       Date:  2013-01-21       Impact factor: 10.190

7.  Regulation and function of miR-214 in pulmonary arterial hypertension.

Authors:  Hannah C Stevens; Lin Deng; Jennifer S Grant; Karine Pinel; Matthew Thomas; Nicholas W Morrell; Margaret R MacLean; Andrew H Baker; Laura Denby
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

Review 8.  STAT3 signaling in pulmonary arterial hypertension.

Authors:  Roxane Paulin; Jolyane Meloche; Sébastien Bonnet
Journal:  JAKSTAT       Date:  2012-10-01

Review 9.  PTEN as a Therapeutic Target in Pulmonary Hypertension Secondary to Left-heart Failure: Effect of HO-3867 and Supplemental Oxygenation.

Authors:  Yazhini Ravi; Chittoor B Sai-Sudhakar; Periannan Kuppusamy
Journal:  Cell Biochem Biophys       Date:  2021-06-16       Impact factor: 2.194

10.  Selective inactivation of PTEN in smooth muscle cells synergizes with hypoxia to induce severe pulmonary hypertension.

Authors:  Henrick Horita; Seth B Furgeson; Allison Ostriker; Kyle A Olszewski; Timothy Sullivan; Leah R Villegas; Michelle Levine; Jane E Parr; Carlyne D Cool; Raphael A Nemenoff; Mary C M Weiser-Evans
Journal:  J Am Heart Assoc       Date:  2013-05-31       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.